IP Library Granted Patent US 7,078,506
Granted Patent B2
US 7,078,506 · App. 10/218,654 · Granted Jul 18, 2006

Canineil-4nucleic acid molecules and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,078,506
App. No.
10/218,654
Granted
Jul 18, 2006
Kind
B2
Abstract

The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins; to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF nucleic acid molecules, including those that encode canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins, respectively; to antibodies raised against such proteins; and to inhibitory compounds that regulate such proteins. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to regulate an immune response in an animal.

Claims (14)

1. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

(a) a nucleic acid sequence encoding a protein having the sequence of SEQ ID NO:2 or SEQ ID NO:20; and

(b) a nucleic acid sequence fully complementary to the nucleic acid sequence of (a).

2. The isolated nucleic acid molecule of claim 1 , wherein said nucleic acid sequence is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:19, and SEQ ID NO:21.

3. The isolated nucleic acid molecule of claim 1 , wherein said nucleic acid sequence is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4 and SEQ ID NO:19.

4. A composition comprising the isolated nucleic acid molecule of claim 1 .

5. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:19, and SEQ ID NO:21.

6. A composition comprising the isolated nucleic acid molecule of claim 5 .

7. An isolated nucleic acid molecule consisting of a nucleic acid sequence selected from the group consisting of:

(a) a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:20;

(b) a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:19 and SEQ ID NO:21; and

(c) a nucleic acid sequence fully complementary to the nucleic acid sequence of (a) or (b).

8. A fragment of the isolated nucleic acid molecule of claim 7 , wherein said fragment is at least 50 nucleotide in length.

9. a composition comprising the isolated nucleic acid molecule of claim 7 .

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 14, 2023
From: JPMORGAN CHASE BANK, N.A.
To: HESKA CORPORATION; DIAMOND ANIMAL HEALTH, INC.; HESKA IMAGING, LLC
Reel/Frame 066012/0887 →
SECURITY INTEREST Recorded Oct 24, 2017
From: HESKA CORPORATION; DIAMOND ANIMAL HEALTH, INC.; HESKA IMAGING, LLC
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 044636/0972 →
SECURITY AGREEMENT Recorded Feb 26, 2009
From: HESKA CORPORATION
To: WELLS FARGO BUSINESS CREDIT, INC.
Reel/Frame 022354/0170 →